Syndax Posts $83.3 Million in Q3 2026 Revenue as Net Loss Narrows

Syndax Pharmaceuticals posted $83.298 million in revenue for the three months ended Sept. 30, 2026, up from $45.871 million in the same 2025 quarter. The company announced the results Nov. 2.

Product revenue totaled $60.743 million and was tied to Revuforj. Collaboration revenue was $22.555 million from the Niktimvo collaboration.

Net loss attributable to common stockholders was $49.433 million, or $0.55 per share. In the same 2025 quarter, the net loss was $60.715 million, or $0.70 per share.

“We delivered another quarter of strong commercial results, generating $83 million in total revenue to Syndax,” CEO Michael A. Metzger said. Syndax develops cancer therapies.